Genetic Score Detects Those at Risk for Sudden Cardiac Death

Translate to Spanish or other 102 languages!

The study, published today in the Journal of the American College of Cardiology, shows that patients with coronary artery disease without severely impaired heart function had the highest polygenic risk score, translating to a 77% increased risk for sudden cardiac death. Image for illustration purposes
The study, published today in the Journal of the American College of Cardiology, shows that patients with coronary artery disease without severely impaired heart function had the highest polygenic risk score, translating to a 77% increased risk for sudden cardiac death. Image for illustration purposes

Mega Doctor News

- Advertisement -

By Cedars-Sinai

Newswise — LOS ANGELES – Researchers in the Smidt Heart Institute at Cedars-Sinai are one step closer to identifying patients at highest risk for developing sudden cardiac death—an electrical malfunction in the heart that causes it to stop beating.

To identify those at highest risk, researchers used a polygenic risk score that has been previously shown successful in predicting coronary artery disease. This Cedars-Sinai study, however, is the first study proven to be effective at identifying coronary artery disease patients at highest risk for sudden cardiac death.

- Advertisement -

The study, published today in the Journal of the American College of Cardiology, shows that patients with coronary artery disease without severely impaired heart function had the highest polygenic risk score, translating to a 77% increased risk for sudden cardiac death.

“In order to better predict and prevent sudden cardiac death, we must first understand the genetic connection between it and coronary artery disease,” said Roopinder Sandhu, MD, MPH,  associate professor of Cardiology, and first author of the study. “We found incorporating information from this genetic risk score improved our ability to predict sudden death beyond the contributions of other known risk markers. Most exciting, the genetics were able to identify patients where sudden death was more likely to limit their life expectancy.”

Unlike heart attacks (myocardial infarctions), which are typically caused by clogged coronary arteries reducing blood flow to the heart muscle, sudden cardiac death most often results from the sudden onset of erratic electrical activity that impairs the pumping function of the heart. Patients may have little or no warning, and the disorder usually causes death within minutes if no resuscitation is performed.

Sudden cardiac death—also called sudden cardiac arrest—accounts for approximately 300,000 deaths each year in the U.S. and is a leading international health problem, responsible for 15% to 20% of all deaths. Coronary artery disease is the most common underlying reason for sudden cardiac death. Sandhu says in the future, this work may help better identify patients who would benefit most from lifesaving therapies like a defibrillator.

- Advertisement -

At present, most sudden cardiac deaths—70%—occur in patients who do not meet current guidelines for prevention with defibrillator therapy. Thus, contemporary practice not only neglects most individuals who develop sudden cardiac deathbut also involves electrophysiologists placing defibrillators in patients with advanced heart disease who are often unlikely to benefit due to limited life expectancy.

The JACC study is based on data from the National Institutes of Health-sponsored PRE-DETERMINE observational study, which has aimed to more accurately identify people at risk for sudden cardiac death among the larger pool of coronary artery disease patients who do not have advanced heart disease.

Christine Albert, MD, MPH, chair of the Department of Cardiology in the Smidt Heart Institute and senior author, said, “This study indicates there is opportunity to identify patients at highest risk for sudden cardiac death, and then offering meaningful, preventative treatment solutions like a defibrillator. Based on our pivotal research, we now have the foundation to achieve this.” 

Funding: PREDETERMINE was supported by research grants from the National Heart, Lung, and Blood Institute R01HL091069, St. Jude Medical Inc., and St. Jude Medical Foundation (to CMA). Genetic analysis was supported by grants 1K08HG010155 and 1U01HG011719 (to A.V.K.) from the National Human Genome Research Institute.

Read more from the Cedars-Sinai Blog: Women’s Hearts at Risk

SEE ORIGINAL STUDY

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

FDA Launches Expedited IND Pilot to Speed Up Clinical Trials

The U.S. Food and Drug Administration today announced the final design of the Expedited Investigational New Drug (IND) Pilot. Accelerating clinical trial timelines and eliminating regulatory hurdles to maintain American leadership in global medical innovation is a core priority for the Trump Administration.

Navigating Cardiovascular Health in Hispanic Communities

Cardiovascular disease is the leading cause of death for Hispanic and Latino people in the United States. But the challenges they face are hardly the whole story, say experts who helped write a new report on the heart health of these communities.

Easy Ways to Turn Picky Eaters Into Happy Eaters

September is National Fruits and Veggies Month. If you have a little one who isn’t a big fan of either, you’re in good company. It’s common for kids to be picky eaters.

New AI Tool Accurately Predicts Lung Cancer Immunotherapy Results

Artificial intelligence (AI) tools can help physicians predict treatment and survival outcomes in patients with advanced non-small cell lung cancer (NSCLC) treated with immunotherapy, according to a new study published in Nature Medicine.
- Advertisement -